OTCMKTS:HNSBF Hansa Biopharma AB (publ) (HNSBF) Stock Price, News & Analysis → The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad) Free HNSBF Stock Alerts $2.93 0.00 (0.00%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$2.93▼$2.9350-Day Range$2.93▼$3.2652-Week Range$2.26▼$5.30VolumeN/AAverage Volume425 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartHeadlinesShort InterestStock AnalysisChartHeadlinesShort Interest Get Hansa Biopharma AB (publ) alerts: Email Address Ad WealthPressIt’s now possible to know the win rate of every trade… BEFORE you take it! Would you like to know the historic win rate of every trade you take before you place it? Well, it’s all possible with these FIVE Candlestick Pattern Cheatsheets. >> You can grab your FREE, laminated copies right here << About Hansa Biopharma AB (publ) Stock (OTCMKTS:HNSBF)Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.Read More HNSBF Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart HNSBF Stock News HeadlinesApril 18, 2024 | prnewswire.comHansa Biopharma interim report January-March 2024April 17, 2024 | markets.businessinsider.comWhat Wall Street expects from Hansa Medical AB's earningsApril 29, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.April 2, 2024 | morningstar.comXbrane Biopharma AB XBRANEApril 2, 2024 | prnewswire.comHansa Biopharma Expects Strong First Quarter 2024 Sales PerformanceMarch 21, 2024 | finance.yahoo.comHansa Biopharma publishes 2023 Annual and Sustainability ReportsFebruary 22, 2024 | prnewswire.comEvan Ballantyne to join Hansa Biopharma as Chief Financial OfficerFebruary 6, 2024 | seekingalpha.comHansa Biopharma AB (publ) 2023 Q4 - Results - Earnings Call PresentationApril 29, 2024 | Paradigm Press (Ad)Biden replacement revealed?A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.February 1, 2024 | markets.businessinsider.comHansa Medical AB earnings: here's what to expectJanuary 6, 2024 | finance.yahoo.comHansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare ConferenceDecember 16, 2023 | morningstar.comHansa Biopharma AB HNSADecember 14, 2023 | finance.yahoo.comImlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantationDecember 7, 2023 | finance.yahoo.comImlifidase demonstrated positive safety, tolerability, and early efficacy outcomes in 15-HMedIdeS-09 phase 2 trial in Guillain-Barré Syndrome (GBS)October 13, 2023 | finance.yahoo.comUpdate on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patientsOctober 11, 2023 | finanznachrichten.deHansa Biopharma AB: Update on ConfIdeS Phase 3 trial of imlifidase in highly sensitized kidney transplant patientsOctober 9, 2023 | finance.yahoo.comHansa Biopharma announces encouraging high-level results for first-in-human trial of HNSA-5487September 1, 2023 | finance.yahoo.comDr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa BiopharmaJuly 20, 2023 | finance.yahoo.comHansa Biopharma half year report 2023July 19, 2023 | finance.yahoo.comFirst patient treated with imlifidase in an investigator-initiated Phase 2 study in ANCA-associated vasculitisJuly 11, 2023 | finance.yahoo.comIdefirix (imlifidase) receives provisional approval in Australia as desensitization treatment in highly sensitized patients prior to kidney transplantationJuly 6, 2023 | benzinga.comHansa Biopharma to host conference call to provide half year results for January-June 2023 and a Business UpdateJuly 4, 2023 | finance.yahoo.comHansa Biopharma AB recognizes a write-up of SEK 1.430 billion in intangible assets related to Idefirix in the financial statements of the parent company - no impact on the consolidated financialsJune 1, 2023 | finance.yahoo.comHansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantationMay 30, 2023 | finance.yahoo.comHansa announces first patient dosed with imlifidase in a global pivotal phase 3 trial in anti-glomerular basement membrane (anti-GBM) diseaseApril 27, 2023 | finance.yahoo.comHansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodiesApril 20, 2023 | msn.comHansa Biopharma provides Q1 updateSee More Headlines Receive HNSBF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Hansa Biopharma AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolOTCMKTS:HNSBF CUSIPN/A CIKN/A Webwww.hansabiopharma.com Phone46 46 16 56 70FaxN/AEmployees168Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesMr. Søren Tulstrup M.Sc (Age 59)President & CEO Comp: $16.12MMr. C. Evan Ballantyne (Age 64)Chief Financial Officer Dr. Christian Kjellman (Age 57)Senior VP & COO Dr. Hitto Kaufmann Ph.D. (Age 53)Chief Scientific Officer Ms. Eva-Maria Joed (Age 55)Vice President of Finance & Administration Mr. Klaus SindahlVP & Head of Investor RelationsMs. Anne Säfström Lanner (Age 55)Senior VP & Chief Human Resources Officer Mr. Emanuel Björne (Age 51)VP & Head of Business Development Dr. Lena Winstedt (Age 55)Head of Science Ms. Vincenza Nigro M.B.A.VP & Head of Medical AffairsMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFW3SBioOTCMKTS:TRSBF60 Degrees PharmaceuticalsNASDAQ:SXTPWAbcamOTCMKTS:ABCZFAdociaOTCMKTS:ADOIFView All Competitors HNSBF Stock Analysis - Frequently Asked Questions How have HNSBF shares performed in 2024? Hansa Biopharma AB (publ)'s stock was trading at $2.2570 at the beginning of the year. Since then, HNSBF stock has increased by 29.8% and is now trading at $2.93. View the best growth stocks for 2024 here. How do I buy shares of Hansa Biopharma AB (publ)? Shares of HNSBF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:HNSBF) was last updated on 4/29/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsAI finds its first serious applicationWall Street StarHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyBiden out June 13; Kamala won’t replace him?Paradigm PressThe A.I. story nobody is telling you (Read ASAP)TradeSmith Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hansa Biopharma AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
